Watson To License Takeda's Actos In Patent Deal

By Richard Vanderford

Law360, New York (March 10, 2010, 2:46 PM ET) -- Takeda Chemical Industrials Ltd. has agreed to license diabetes medication Actos to rival Watson Pharmaceuticals Inc. and drop a long-running patent infringement case, the generics maker announced Wednesday.

Under the terms of the deal, which resolves litigation in the U.S. District Court for the Southern District of New York, Watson will gain a nonexclusive royalty-free license to Takeda's U.S. patents covering Actos, the brand-name for pioglitazone hydrochloride, Watson said in a statement.

Actos is an oral medication used to reduce insulin resistance in type 2 diabetics....
To view the full article, take a free trial now.

Already a subscriber? Click here to login

You must correct or enter the following before you can submit this form:

All fields required

  5. Required

Only Law360 gives you:

Non-stop coverage of high-stakes litigation across 30 practices

Real-time tracking and reports on 10,000+ companies, firms and industries

Over 80,000 attorney profiles with neutral data collected from active lawsuits

Research tools to find cases, court documents, attorneys and companies

Customized feeds and alerts that can easily be shared with colleagues

In-depth expert analysis from high-profile attorneys at top firms

Access to our vault with over 75,000 original articles